MIRCERA.com

The key features of MIRCERA are listed below.  A summary of the information and clinical evidence supporting each of these statements can be viewed on separate pages by clicking on the statement. 

 

MIRCERA – through its different receptor interaction and longer half-life – delivers sustained anaemia management.

 

MIRCERA achieves target haemoglobin (Hb) levels and provides stable and sustained Hb levels during maintenance therapy with once-monthly dosing in all CKD patient types.

 

The safety of MIRCERA is comparable to shorter-acting erythropoiesis-stimulating agents (ESAs).

 

Successful conversion to once-monthly MIRCERA can be achieved with consistent Hb stability.